Last updated: 25 June 2024 at 8:03pm EST

Dr. Louise Rodino-Klapac Ph.D. Net Worth




The estimated Net Worth of Louise Rodino Klapac is at least $10.3 millió dollars as of 21 June 2024. Dr Klapac owns over 6,250 units of Sarepta Therapeutics Inc stock worth over $9,542,330 and over the last 4 years he sold SRPT stock worth over $0. In addition, he makes $739,054 as Chief Scientific Officer and Head of R&D at Sarepta Therapeutics Inc.

Dr D SRPT stock SEC Form 4 insiders trading

Dr has made over 2 trades of the Sarepta Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 6,250 units of SRPT stock worth $802,438 on 21 June 2024.

The largest trade he's ever made was exercising 6,250 units of Sarepta Therapeutics Inc stock on 21 June 2024 worth over $802,438. On average, Dr trades about 669 units every 63 days since 2020. As of 21 June 2024 he still owns at least 74,323 units of Sarepta Therapeutics Inc stock.

You can see the complete history of Dr Klapac stock trades at the bottom of the page.





Dr. Louise Rodino-Klapac Ph.D. biography

Dr. Louise Rodino-Klapac Ph.D. is the Chief Scientific Officer and Head of R&D at Sarepta Therapeutics Inc.

What is the salary of Dr D?

As the Chief Scientific Officer and Head of R&D of Sarepta Therapeutics Inc, the total compensation of Dr D at Sarepta Therapeutics Inc is $739,054. There are 7 executives at Sarepta Therapeutics Inc getting paid more, with Gilmore O'Neill having the highest compensation of $5,168,110.



How old is Dr D?

Dr D is 43, he's been the Chief Scientific Officer and Head of R&D of Sarepta Therapeutics Inc since . There are 16 older and no younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.

Insiders trading at Sarepta Therapeutics Inc

Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry és M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.



What does Sarepta Therapeutics Inc do?

sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.



What does Sarepta Therapeutics Inc's logo look like?

Sarepta Therapeutics Inc logo

Complete history of Dr Klapac stock trades at Sarepta Therapeutics Inc

Dátum
#
Cég
Az érdekelt
Trans.
Tranzakció
Részvények száma Ár per részvény Teljes ár Részvények szíma után Forrás
21 Jun 2024 Louise Rodino Klapac
Head of R, D és CSO
Opció Gyakorlat 6,250 $160.72 $1,004,500
21 Jun 2024
74,323
24 Nov 2021 Louise Rodino Klapac
Head of R, D és CSO
Megvenni 3,780 $79.33 $299,867
24 Nov 2021
65,678


Sarepta Therapeutics Inc executives and stock owners

Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include: